X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

NeuroVive reallocate research resources from the Asian subsidiary of the parent company

Yuvraj_pawp by Yuvraj_pawp
25th January 2017
in Research & Development

NeuroVive Pharmaceutical AB , a company in mitochondrial medicine announced that research resources and activities of the Taiwan-based subsidiary redirected to the parent company NeuroVive Pharmaceutical AB.

At a general meeting of NeuroVive Pharmaceutical Asia, Inc. was approved an agreement whereby operations in Taiwan will be sold to current Taiwanese shareholders.

Under the agreement, NeuroVive Pharmaceutical AB will receive about 5 million before administrative expenses. Beyond this, NeuroVive and partner Foundation Asia Pacific Ltd., re-acquire the Hong Kong-based subsidiary, NeuroVive Pharmaceutical Asia Ltd., which holds the Asian licensing rights for Neuro State and the agreements with Chinese pharmaceutical company Sihuan Pharmaceutical and Sanofi Korea. The ownership of the Hong Kong company will be NeuroVive Pharmaceutical AB (about 82.5%) and Foundation Asia Pacific Ltd. (About 17.5%). Through the agreement, other assets, which were previously licensed to NeuroVive Asian companies, to NeuroVive Pharmaceutical AB.


In line with the company’s newly implemented two-part business model, which involves an increased focus on early projects for major specialist indications for licensing in the preclinical phase, and own clinical development of orphan drug, the resources of the Taiwan-based subsidiary that distributed and concentrated on research and development activities Parent NeuroVive Pharmaceutical AB.


“This decision is fully in line with the new corporate strategy and enables further focus on further developing the company’s project portfolio. We will release resources to operate until the early research projects as efficiently as possible, “said Erik Kinnman NeuroVive CEO. “We want to thank our colleagues in Taiwan for their cooperation in all the work, and in this process and wish them well in their future activities,” he adds.


The subsidiary in Taiwan was established in 2014 to manage the planned clinical activities locally in the region and for the development of research projects under license from its parent company NeuroVive Pharmaceutical AB and others.


If NeuroVive

NeuroVive Pharmaceutical AB is a leading company in mitochondrial medicine. The company is focused on the research and development of targeted drug candidates that maintain mitochondrial integrity and function for indications where there is a large unmet medical need. The company’s strategy includes its own development of medicines for rare diseases, through clinical development phase all the way to the market. For most of the company’s projects targeting major indications with high potential, the strategy is licensing the preclinical phase. NeuroVive value creation projects done in collaboration and networking with leading research institutions in mitochondrial medicine and expert resources in drug development and pharmaceutical production.


NeuroVive has a project in the early clinical phase II for the treatment of moderate to severe traumatic brain injury. The drug candidate NeuroSTAT® has orphan drug status in Europe and the US. The research portfolio includes several projects in late discovery which covers areas such as genetic mitochondrial diseases and cancer as well as neurological and metabolic diseases such as NASH.


NeuroVive is listed on Nasdaq Stockholm (ticker: NVP). Shares are available for trading in the US on the OTCQX marketplace Best market.


For investor and / or media queries, please contact:

Cecilia Hofvander,
NeuroVive,
Tel: 046-275 62 21 or
ir@neurovive.com


Charles Athlé Nelson,
NeuroVive representative in the USA,
Tel +1 212 961 6277 or
ir.usa@neurovive.com


NeuroVive Pharmaceutical AB (publ)

Medicon Village, 223 81 Lund,
Sweden

Tel: 046-275 62 20 (switchboard)
www.neurovive.com

Previous Post

Jitsubo and Japanese pharma company Enter License Agreement and Collaboration for cardiovascular disease

Next Post

Live broadcast of session on biosimilars and EU regulation: still time to join us!

Related Posts

Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Manufacturing

Commercial Success In New Biopharmaceutical Innovation Era

21st May 2022
Manufacturing

Proteros and AstraZeneca Boost Collaboration Agreement

18th May 2022
SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory
Middle East and South Asia

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

22nd March 2022
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Press Statements

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

17th January 2022
COVID-19 Impact On Changing Pharma Research And Development
News

COVID-19 Impact On Changing Pharma Research And Development

12th January 2022
immuno-oncology therapies
Drug Development

AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

19th November 2021
Next Post

Live broadcast of session on biosimilars and EU regulation: still time to join us!

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In